Civica Welcomes Dr. Dave Sehgal as Chief Manufacturing Officer
Civica Welcomes Dr. Dave Sehgal as Chief Manufacturing Officer
Civica has announced an exciting new addition to its leadership team with the appointment of Dr. Dave Sehgal as the Chief Manufacturing Officer and Supply Chain Officer. His experience and expertise are expected to play a crucial role in advancing Civica's mission to make high-quality medicines accessible.
Leading the Manufacturing Strategy
In his new position, Dr. Sehgal will develop and oversee the manufacturing strategy and operations for Civica, a nonprofit generic pharmaceutical company committed to addressing drug shortages. Reporting directly to the company's President and CEO, Ned McCoy, his vision will help navigate the complexities of pharmaceutical manufacturing.
Ned McCoy expressed enthusiasm about Dr. Sehgal's arrival, emphasizing his vast knowledge in pharmaceutical manufacturing that will significantly benefit the operations at Civica. His leadership is particularly pivotal as the company prepares to ramp up production at its manufacturing facility in Petersburg.
Experience that Matters
Dr. Sehgal's impressive background spans nearly three decades in the pharmaceutical sector, particularly in the areas of vaccines, biologics, and small molecule manufacturing. His extensive experience includes significant roles in technical services, quality assurance, and process development. He is well-prepared to lead Civica into a new era of growth and efficiency.
Prior to joining Civica, Dr. Sehgal served as the Vice President and Global Processing Engineering Head at CSL-Behring. There, he managed a vast team of scientists and engineers, fostering innovation and progress across multiple global locations. His diverse positions at various leading firms such as FUJIFILM Diosynth Biotechnologies and Novartis have shaped his comprehensive understanding of the industry.
Investing in High-Quality Medicines
Dr. Sehgal's excitement about his new role is palpable. He is dedicated to the vision of providing high-quality generic medicines to patients, manufactured in the United States. The Petersburg facility, an essential asset for Civica, is a 140,000 square foot plant equipped with advanced technology and skilled personnel. It is set to employ over 200 workers, with plans for additional hiring to further bolster its operations.
This facility is capable of producing a staggering volume of medicines each year, including 90 million vials and 50 million syringes. As it nears certification by regulatory authorities, the facility is expected to begin distribution by 2026, marking a significant milestone for Civica’s supply chain.
Commitment to Excellence
The appointment of Dr. Sehgal underscores Civica's unwavering dedication to operational excellence. As a nonprofit, Civica exists to provide a stable and affordable supply of crucial medications to patients throughout the U.S. By focusing on quality and accessibility, Civica aims to alleviate the impacts of drug shortages that have plagued the healthcare system for years.
About Civica
Civica is a nonprofit organization that emerged from a collective effort to tackle the persistent issue of drug shortages in the United States. Founded by health systems and philanthropies, Civica's mission aims to stabilize the market and ensure that essential medicines remain within reach for everyone who needs them.
Media Contact Information
Civica's media inquiries can be directed to Liz Power, Vice President of Communications, reachable at 860 501 3849.
Frequently Asked Questions
What role will Dr. Sehgal take at Civica?
Dr. Sehgal will serve as the Chief Manufacturing Officer and Supply Chain Officer, focusing on the company’s manufacturing strategy.
What is Civica's mission?
Civica aims to address drug shortages by providing a consistent supply of high-quality generic medicines to U.S. patients.
How large is the Petersburg facility?
The Petersburg facility spans 140,000 square feet and has plans for significant production capacity.
What medicines will Civica produce?
Civica plans to manufacture a variety of generic sterile injectable medicines, including vials and syringes.
How can I contact Civica for media inquiries?
Media inquiries can be directed to Liz Power, Vice President of Communications at Civica.
About The Author
Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.